Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004584
Status:
COMPLETED
Last Update Posted:
2011-05-04
First Post:
2000-02-10
Brief Title:
Safety and Effectiveness of a New Protease Inhibitor BMS-232632 in HIV-Positive Patients Who Have Received Previous Treatment
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor BMS-232632 in Combination Regimens as Compared to a Reference Combination Regimens in Antiretroviral-Experienced HIV-Infected Subjects
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor a type of anti-HIV drug called BMS-232632 Doctors will compare an anti-HIV drug combination that includes BMS-232632 to a drug combination that includes ritonavir
Detailed Description:
This is a three-arm study patients are randomized to receive BMS-232632 at two different doses or RTV in combination with SQV and two nucleoside analogues over 48 weeks Randomization is stratified for baseline phenotypic sensitivity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AI424-009 | None | None | None |